Pliant Therapeutics logo

Pliant Therapeutics Funding & Investors

South San Francisco, CA

Pliant Therapeutics is focused on discovering, developing and commercializing breakthrough treatments for fibrotic diseases. By harnessing the therapeutic potential of integrin biology and TGF-β modulation, Pliant aims to prevent or even reverse fibrosis to address the needs of many patients. The company also aims to build a patient registry for certain areas of fibrotic disease to both increase understanding of natural disease progression, and fuel biomarker discovery. Pliant’s co-founders include world-renowned researchers from University of California, San Francisco (UCSF), who bring broad experience in fibrosis biology and small molecule chemistry. Together, the Pliant team is dedicated to translating scientific advances in fibrosis biology into novel therapies for patients in need.

pliantrx.com

Total Amount Raised: $694,945,152

Pliant Therapeutics Funding Rounds

  • Post Ipo Equity

    $287,500,000

  • Post Ipo Equity

    $200,000,000

  • Series C

    $100,445,146

    Series C Investors

    Novartis
    Farallon Capital Management
    Redmile Group
    Surveyor Capital
    Menlo Ventures
    Cowen
    S-Cubed Capital
    Schroder Adveq
    Eventide
    Logos Capital
    Cormorant Asset Management
    Agent Capital
  • IPO

    Unknown

  • Series B

    $62,000,000

    Series B Investors

    Cowen
    Eventide
    Schroder Adveq
    Agent Capital
    Menlo Ventures
    S-Cubed Capital
  • Series A

    $45,000,000

    Series A Investors

    Third Rock Ventures
    pH Pharma
Funding info provided by Diffbot.